Oxford, UK, April 28th, 2026 — Theolytics, a clinical‑stage biotechnology company developing next‑generation oncolytic immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating intraperitoneal (IP) administration of THEO‑260 for the treatment of women with Platinum‑Resistant Ovarian Cancer (PROC) (NCT07211659).
The US trial, OCTOPOD‑IP, will be the second clinical trial investigating THEO‑260 in this indication, the first being the ongoing Phase 1/2a trial called OCTOPOD‑IV in the UK, Spain and Canada (NCT06618235).
Positioned to tackle the complex, immune‑suppressed nature of advanced solid tumours, THEO‑260 is designed to target and eliminate cancer cells and cancer‑associated fibroblasts (CAFs) while inducing immune activation. PROC represents a prototype of a broader category of stroma‑rich solid tumours for which THEO‑260 is being developed.
The US OCTOPOD‑IP trial will assess the safety and tolerability of THEO‑260 administered directly to the peritoneal cavity (IP delivery) in PROC patients and include extensive biomarker studies to showcase THEO‑260's differentiated mode of action.
The trial is sponsored by Theolytics and will be run under the guidance of principal investigator Amir Jazaeri, MD, Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery at The University of Texas MD Anderson Cancer Center.